STENTYS Wins Large Regional Tender in Middle East

PRINCETON, N.J. and PARIS – October 20, 2014 – STENTYS (FR0010949404 – STNT), a medical technology company commercializing the world’s first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), today announced that the 2014 SGH tender has awarded more than 1,000 coronary stents to STENTYS.

The SGH Tender is a group purchasing program that serves the Ministries of Health in the six GCC members states: United Arab Emirates, Kingdom of Bahrain, Kingdom of Saudi Arabia, Sultanate of Oman, State of Qatar and State of Kuwait. It is renewed every year for a period of one year.

Gonzague Issenmann, Chief Executive Officer and co-founder of STENTYS, stated: "The successful outcome of this tender is a concrete result of our commercial strategy in the Middle East. It started by establishing ties with strong local partners and was accelerated recently with the opening of a branch office in Dubai. We are very satisfied with this strategy and will continue its implementation to serve cardiologists worldwide."

- Upcoming financial publication

STENTYS expects to publish its revenues for the 3rd quarter on October 23, 2014.

About STENTYS
STENTYS is developing and commercializing innovative solutions for the treatment of patients with acute myocardial infarction (AMI, or heart attack) and complex coronary artery disease. STENTYS's Self-Apposing® Stents are designed to adapt to vessels with ambiguous or fluctuating diameters, particularly in the post-infarction phase, in order to prevent the malapposition problems associated with conventional stents. In the APPOSITION III clinical trial, STENTYS stents demonstrated a very low one year mortality rate among 1,000 high-risk AMI patients when compared to recent studies with conventional stents. More information is available at www.stentys.com.

Forward Looking Statements
This press release contains forward-looking statements about the Company’s business. Such forward looking statements are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which it will operate in the future which may not be accurate. Such forward-looking statements involve known and unknown risks which may cause the Company’s actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, risks associated with the development and commercialization of the Company’s products, market acceptance of the Company’s products, its ability to manage growth, the competitive environment in relation to its business area and markets, its ability to enforce and protect its patents and proprietary rights, uncertainties related to the U.S. FDA approval process, slower than expected rates of patient recruitment for clinical trials, the outcome of clinical trials, and other factors, including those described in the Section 4 "Risk Factors" of the Company’s 2011 Registration Document (document de référence) filed with the French Autorité des Marchés Financiers on August 27, 2013 under number R.13-040 as such section may be updated from time to time.

STENTYS
Stanislas Piot
CFO
Tel.: +33 (0)1 44 53 99 42
stan.p@stentys.com

NewCap
Investor Relations / Strategic Communications
Dusan Oresansky / Pierre Laurent
Tel.: +33 (0)1 44 71 94 93
stentys@newcap.fr

LifeSci Advisors LLC
Andrew McDonald
Tel: +1.646.597.6987
andrew@lifesciadvisors.com

STENTYS is listed on Comp. B of Euronext Paris
ISIN: FR0010949404 – Ticker: STNT